Table 1.
Patient characteristics at baseline
| Characteristic | |
|---|---|
| Patients, N |
74 |
| Gender, n (%) |
|
| Male |
46 (62.2) |
| Female |
28 (37.8) |
| Age, years, median (range) |
56 (23–79) |
| Time from diagnosis, months, median (range) |
31 (5–206) |
| Melanoma diagnosis, n (%) |
|
| Cutaneous |
57 (77.0) |
| Uveal |
9 (12.2) |
| Mucosal |
2 (2.7) |
| Unknown |
6 (8.1) |
| Presence of brain metastases |
11 (14.9) |
| M stage, n (%) |
|
| M0 (unresectable stage III) |
2 (2.7) |
| M1a |
16 (21.6) |
| M1b |
2 (2.7) |
| M1c |
53 (71.6) |
| Unknown |
1 (1.4) |
| ECOG PS |
|
| 0 |
43 (58.1) |
| 1 |
29 (39.2) |
| 2 |
2 (2.7) |
| LDH |
|
| Median (range), units/L |
466 (139–4416) |
| >Upper limit of normal (480 units/L), n (%) |
37 (50) |
| Number of prior therapies for metastatic disease, median (range) | 2 (1–5) |
ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, PS performance status.